ClinVar Miner

Submissions for variant NM_000263.4(NAGLU):c.1694G>A (p.Arg565Gln) (rs104894598)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 6
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
GeneDx RCV000433629 SCV000521202 pathogenic not provided 2016-09-28 criteria provided, single submitter clinical testing The R565Q variant in the NAGLU gene has been reported previously in mucopolysaccharidosis type IIIB, in affected individuals who were compound heterozygous for the R565Q variant and another variant (Bunge et al., 1999; Valstar et al., 2010; Héron et al., 2011; Tang et al., 2013). The R565Q variant was not observed at any significant frequency in approximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations. The R565Q variant is a semi-conservative amino acid substitution, which may impact secondary protein structure as these residues differ in some properties. This substitution occurs at a position that is conserved across species. In silico analysis predicts this variant is probably damaging to the protein structure/function. Missense variants in the same codon (R565W, R565P, R565L) have been reported in the Human Gene Mutation Database in association with mucopolysaccharidosis type IIIB (Stenson et al., 2014), supporting the functional importance of this codon. We interpret R565Q as a pathogenic variant.
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000590258 SCV000696367 pathogenic Sanfilippo syndrome 2016-06-17 criteria provided, single submitter clinical testing Variant summary: The NAGLU c.1694G>A (p.Arg565Gln) variant involves the alteration of a conserved nucleotide. 3/4 in silico tools predict a damaging outcome (SNPs&GO not captured due to low reliability index). Arg565 is highly conserved across species, and two other mutations have been reported at the Arg565 codon (R565Q, R565P) (Beesley et al 1998; Bunge et al 1999; Weber et al 1999), which suggests that this codon is a mutational hotspot in the NAGLU gene. This variant was found in 4/115194 control chromosomes at a frequency of 0.0000347, which does not exceed the estimated maximal expected allele frequency of a pathogenic NAGLU variant (0.0025). The variant has been identified in multiple MPS3B patients in compound heterozygous state and has been shown to co-segregate with disease in at least one family (Tang_CCA_2013). Compound heterozygous patients have been shown to have <10% of normal NAGLU activity. In addition, OMIM classified this variant as pathogenic. Taken together, this variant is classified as Pathogenic.
Invitae RCV001043861 SCV001207628 pathogenic Mucopolysaccharidosis, MPS-III-B; Charcot-Marie-Tooth disease, axonal type 2V 2020-10-02 criteria provided, single submitter clinical testing This sequence change replaces arginine with glutamine at codon 565 of the NAGLU protein (p.Arg565Gln). The arginine residue is highly conserved and there is a small physicochemical difference between arginine and glutamine. This variant is present in population databases (rs104894598, ExAC 0.006%). This variant has been observed in combination with another NAGLU variant in individuals affected with mucopolysaccharidosis type III (PMID: 9950362, 20852935, 23380547, 28751108). ClinVar contains an entry for this variant (Variation ID: 30795). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: Deleterious; PolyPhen-2: Probably Damaging; Align-GVGD: Class C0). This variant disrupts the p.Arg565 amino acid residue in NAGLU. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 10094189, 15933803, 23430803). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic.
CeGaT Praxis fuer Humangenetik Tuebingen RCV000433629 SCV001246601 pathogenic not provided 2019-11-01 criteria provided, single submitter clinical testing
OMIM RCV000023780 SCV000045071 pathogenic Mucopolysaccharidosis, MPS-III-B 2011-09-21 no assertion criteria provided literature only
Counsyl RCV000023780 SCV000788474 likely pathogenic Mucopolysaccharidosis, MPS-III-B 2017-09-29 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.